Please login to the form below

Not currently logged in
Email:
Password:

Alzheimer's disease

This page shows the latest Alzheimer's disease news and features for those working in and with pharma, biotech and healthcare.

Biogen bulks up in Alzheimers again with $2.7bn Sangamo deal

Biogen bulks up in Alzheimer’s again with $2.7bn Sangamo deal

Biogen has made another big investment play in Alzheimer’s disease, penning a $350m upfront agreement with gene-editing specialist Sangamo for rights to tau-targeting drug ST-501 as part ... Tau is emerging as a target for drug development in

Latest news

More from news
Approximately 62 fully matching, plus 322 partially matching documents found.

Latest Intelligence

  • Alzheimer’s: the search for a cure Alzheimers: the search for a cure

    reduction in tauopathy,” said Paul Aisen, director of the Alzheimer’s Therapeutic Research Institute, at the Clinical Trials on Alzheimer’s Disease meeting where Biogen presented its data. ... Canaccord Genuity analysts forecast peak sales of

  • Great expectations: the urgent need for common purpose in Alzheimer’s disease Great expectations: the urgent need for common purpose in Alzheimers disease

    By Andrew Harrison. A few years ago, when communicating the phase 3 data of a major trial in Alzheimer’s disease (AD), our prime goal was focused on accuracy of reporting ... Most of us will have experience of family or friends with Alzheimer’s or

  • Can protein degraders unlock ‘undruggable’ drug targets? Can protein degraders unlock ‘undruggable’ drug targets?

    Now, interest is growing in a largely-untapped approach to targeting disease-associated proteins, particularly those that for many years have been considered ‘undruggable’. ... C4 also has a collaboration in place with Biogen focusing on neurological

  • Detecting Alzheimer’s ahead of a cure Detecting Alzheimers ahead of a cure

    The test works by identifying amyloid-beta (Abeta) proteins, which build up on the brains of those living with Alzheimer’s and which have a key link to the disease, although ... Alzheimer’s R&D has had to diversify as companies and researchers become

  • A roadmap to the successful treatment of Alzheimer’s disease A roadmap to the successful treatment of Alzheimers disease

    Yet more than 100 years after the discovery of Alzheimer’s disease, we still do not have a cure. ... Today, Alzheimer’s disease is typically diagnosed once symptoms are already clinically present.

More from intelligence
Approximately 5 fully matching, plus 29 partially matching documents found.

Latest appointments

  • J&J’s clinical research neuroscience director joins MedAvante J&J’s clinical research neuroscience director joins MedAvante

    Prior to this, he was medical director, global medical affairs for Janssen's Alzheimer's disease immunotherapy unit from June 2011 to May 2013. ... He also brings extensive experience in psychiatry, neurology and dermatology, making him an ideal addition

  • Asceneuron appoints chief medical officer Asceneuron appoints chief medical officer

    Alzheimer's disease. ... His outstanding track record and expertise in neurodegenerative disease are crucial as we are about to progress our first highly brain penetrant and orally bioavailable tau modifier into the clinic for

  • Pfizer appoints chief scientific officer Pfizer appoints chief scientific officer

    Having first joined Harvard in 1989, Dr Isacson's work in neurogenerative disorders, particularly for Parkinson's disease, has become internationally renowned with his laboratory now one of the leading academic ... s disease, where we are working to

  • Chase adds former Allergan execs to leadership team Chase adds former Allergan execs to leadership team

    With its robust intellectual property, pharmaceutical assets and elegant development strategy, Chase has the opportunity to profoundly reshape the approach to the symptomatic treatment of Alzheimer's disease. ... disease.”. 20th June 2016.

  • Eisai recruits Pfizer and Sanofi execs to neurology group Eisai recruits Pfizer and Sanofi execs to neurology group

    Eisai has also appointed Beyhan Zaim to its US Neurology Business Group as VP, commercial development and Alzheimer's Disease global lead. ... As global lead for Alzheimer's Disease she will also be tasked with developing strategies and heading internal

More from appointments
Approximately 0 fully matching, plus 18 partially matching documents found.

Latest from PMHub

  • Digital therapeutics and their impact on society

    Head of Customer Experience Elisa del Galdo explores how healthcare technology can help chronic disease patients and asks what makes a good digital therapeutic? ... This is in part due to the explosive, bordering on unmanageable, increase in chronic

  • Are we ready for an Alzheimer's disease modifying treatment

    Millions of people across the globe have Alzheimer’s disease and currently, there is no cure. ... However, Alzheimer’s disease-modifying treatments (DMTs) have not progressed as much in the last 15 years as we all hoped.

  • Diagnosing the lag in neuropsychiatric treatments

    Europe spends £690 billion a year on brain disorders, more than both cardiovascular disease and oncology combined. ... Neurological and psychiatric disorders (collectively known as neuropsychiatric disorders), such as Alzheimer’s disease and

  • 'Fake news': battling misinformation in healthcare

    An article published just three days later, again from ‘The Telegraph’ , plays on the  growing threat of Alzheimer’s. ... The article is entitled ‘Alzheimer’s disease can be spotted through simple eye test’ and whilst this article is based

  • Havas Lynx shines a spotlight on carers

    Commenting on the white paper’s findings, Havas Lynx CEO, Dave Hunt, said:. ... References:. Alzheimer’s Disease International (2013) http://bit.ly/2nPw6QK (Accessed April 2017). Carers UK (2015)   (Accessed April 2017).

More from PMHub
Approximately 2 fully matching, plus 12 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

Women in science
The role of women in science and technology
Why the lack of female leaders in pharma and life sciences is a problem that still needs to be fixed...
Maria Dahl
China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances
China secures a place at the forefront of innovative medicine...
Virtual Research Grants Submission and Approval Program
Impetus Digital summarizes how a client established an independent grant review committee and a virtual grant submission and approval program, without having to travel and meet in person....

Infographics